Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
Dana-Farber Cancer Institute
Incyte Corporation
M.D. Anderson Cancer Center
Brown University
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
CRISPR Therapeutics
Incyte Corporation
Children's Oncology Group
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Seattle Children's Hospital
Scripps Translational Science Institute
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Amgen
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Pharmacyclics LLC.
BeiGene
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
OrphAI Therapeutics
Celgene
City of Hope Medical Center
Amgen
Kyowa Kirin Co., Ltd.
Amgen
Amgen
Therapeutic Advances in Childhood Leukemia Consortium
Pfizer
Jazz Pharmaceuticals
National Institutes of Health Clinical Center (CC)
University of Nebraska